Company: LBRX
Filing Date: 2025-08-22
Form Type: S-1
Source: 0001193125-25-186467
Chunk: 136

Company: LB PHARMACEUTICALS INC
Filing Date: 2025-08-22
Form: S-1
Chunk 136
---
 an initial public offering price of $ , the midpoint of the estimated offering price range set forth on the cover page of this prospectus, after deducting underwriting discounts and commissions and estimated offering expenses payable by us. The pro forma and pro forma as adjusted information are illustrative only and following the completion of this offering will be adjusted based on the actual initial public offering price and other terms of this offering determined at pricing. You should read this information in conjunction with our financial statements and the related notes included elsewhere in this prospectus, the section of this prospectus titled “Management’s Discussion and Analysis of Financial Condition and Results of Operations” and other financial information contained in this prospectus. The number of shares of our common stock to be outstanding after this offering is based on 85,094,050 shares of common stock outstanding as of June 30, 2025, after giving effect to the conversion of all outstanding shares of our convertible preferred stock into 78,072,306 shares of common stock upon the closing of this offering and excludes:

| • |     | 11,923,082 shares of common stock issuable upon the exercise of outstanding stock options under our 2023 Plan as 
 of June 30, 2025, at a weighted-average exercise price of $1.50 per share;                                       |

| • |     | 779,500 shares of common stock issuable upon the exercise of outstanding stock options under our 2018 Plan as of 
 June 30, 2025, at a weighted-average exercise price of $2.38 per share;                                          |

89

| • |     | 290,000 shares of common stock issuable upon the exercise of outstanding stock options under our 2017 Plan as of 
 June 30, 2025, at a weighted-average exercise price of $1.79 per share;                                          |

| • |     | 695,961 shares of our common stock issuable upon the exercise of Class A common stock warrants outstanding                                                              
 as of June 30, 2025, with an exercise price of $0.01 per share, as more fully described in the section titled “Description of Capital Stock—Warrants—Class A Warrants;” |

| • |     | 882,948 shares of our common stock issuable upon the exercise of Class B common stock warrants outstanding                                                              
 as of June 30, 2025, with an exercise price of $0.01 per share, as more fully described in the section titled “